BridgeBio Pharma will present Phase 2 data on hypoparathyroidism and skeletal dysplasia at ASBMR Annual Meeting 2025.
Quiver AI Summary
BridgeBio Pharma, Inc. announced that it will present Phase 2 data on post-surgical hypoparathyroidism and skeletal dysplasia at the ASBMR Annual Meeting 2025 in Seattle from September 5-8. The oral presentation will focus on the effects of the calcilytic Encaleret, which reduced urinary calcium while maintaining blood calcium levels in patients with post-surgical hypoparathyroidism. Additionally, two poster sessions will showcase research on the effectiveness of low-dose Infigratinib therapy in improving bone growth in a mouse model of hypochondroplasia and on skull measures in mouse models of Crouzon/Pfeiffer syndromes. BridgeBio, founded in 2015, is dedicated to developing transformative medicines for genetic diseases, with a pipeline that spans from early research to advanced clinical trials.
Potential Positives
- BridgeBio Pharma is showcasing significant advancements in their research at a prestigious conference, which can enhance their visibility and credibility in the biopharmaceutical industry.
- The presentation of Phase 2 data on post-surgical hypoparathyroidism highlights the effectiveness of their oral calcilytic drug, potentially attracting interest from investors and healthcare professionals.
- The inclusion of multiple presentations and posters at the ASBMR Annual Meeting demonstrates the breadth of BridgeBio's research in genetic diseases, potentially positioning the company as a leader in this field.
Potential Negatives
- The press release does not disclose any results or outcomes from the Phase 2 trial, leaving stakeholders without critical information on the drug's efficacy or safety.
- There's no mention of any upcoming regulatory milestones or plans, which could raise concerns about the company's future direction and potential for market introduction.
- By featuring mouse models for skeletal dysplasias rather than human data, the release may lead to skepticism about the relevance and applicability of the findings to actual patient populations.
FAQ
What will BridgeBio present at the ASBMR Annual Meeting 2025?
BridgeBio will present Phase 2 data on post-surgical hypoparathyroidism and skeletal dysplasia research.
Who will present the oral session on post-surgical hypoparathyroidism?
Iris Hartley, M.D., from the National Institutes of Health will present the oral session.
When is the ASBMR Annual Meeting 2025?
The ASBMR Annual Meeting 2025 will take place from September 5 to 8 in Seattle, WA.
What are the topics of the poster sessions BridgeBio will present?
The poster sessions will focus on Infigratinib’s effects on hypochondroplasia and Crouzon/Pfeiffer syndromes.
What is BridgeBio's focus as a biopharmaceutical company?
BridgeBio focuses on discovering and delivering transformative medicines for genetic diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BBIO Insider Trading Activity
$BBIO insiders have traded $BBIO stock on the open market 43 times in the past 6 months. Of those trades, 0 have been purchases and 43 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:
- GENETIC DISORDER L.P. KKR has made 0 purchases and 2 sales selling 12,000,000 shares for an estimated $402,960,000.
- GLOBAL INVESTORS LP VIKING sold 3,500,000 shares for an estimated $154,000,000
- NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 21 sales selling 437,312 shares for an estimated $17,054,035.
- CHARLES J HOMCY has made 0 purchases and 3 sales selling 300,000 shares for an estimated $13,912,442.
- FRANK MCCORMICK sold 100,000 shares for an estimated $4,422,800
- ANDREW LO sold 100,000 shares for an estimated $3,849,900
- THOMAS TRIMARCHI (President and CFO) has made 0 purchases and 3 sales selling 59,590 shares for an estimated $2,961,803.
- ANDREA ELLIS has made 0 purchases and 3 sales selling 57,167 shares for an estimated $2,212,683.
- HANNAH VALANTINE has made 0 purchases and 6 sales selling 21,874 shares for an estimated $798,506.
- MARICEL APULI (Chief Accounting Officer) has made 0 purchases and 2 sales selling 2,026 shares for an estimated $84,949.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BBIO Hedge Fund Activity
We have seen 221 institutional investors add shares of $BBIO stock to their portfolio, and 156 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KOHLBERG KRAVIS ROBERTS & CO. L.P. removed 6,000,000 shares (-31.2%) from their portfolio in Q2 2025, for an estimated $259,080,000
- VIKING GLOBAL INVESTORS LP removed 3,500,000 shares (-15.9%) from their portfolio in Q2 2025, for an estimated $151,130,000
- CITADEL ADVISORS LLC removed 2,598,708 shares (-88.7%) from their portfolio in Q2 2025, for an estimated $112,212,211
- FARALLON CAPITAL MANAGEMENT LLC added 2,169,000 shares (+37.8%) to their portfolio in Q2 2025, for an estimated $93,657,420
- JANUS HENDERSON GROUP PLC added 2,105,133 shares (+29.4%) to their portfolio in Q2 2025, for an estimated $90,899,642
- MACQUARIE GROUP LTD added 2,003,713 shares (+2189.3%) to their portfolio in Q2 2025, for an estimated $86,520,327
- D. E. SHAW & CO., INC. added 1,998,104 shares (+2403.0%) to their portfolio in Q2 2025, for an estimated $86,278,130
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BBIO Analyst Ratings
Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 13 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 08/29/2025
- Cantor Fitzgerald issued a "Overweight" rating on 07/29/2025
- Jefferies issued a "Buy" rating on 07/14/2025
- Citigroup issued a "Buy" rating on 07/11/2025
- Oppenheimer issued a "Outperform" rating on 07/09/2025
- Wells Fargo issued a "Overweight" rating on 06/30/2025
- B of A Securities issued a "Buy" rating on 06/25/2025
To track analyst ratings and price targets for $BBIO, check out Quiver Quantitative's $BBIO forecast page.
$BBIO Price Targets
Multiple analysts have issued price targets for $BBIO recently. We have seen 14 analysts offer price targets for $BBIO in the last 6 months, with a median target of $66.5.
Here are some recent targets:
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $70.0 on 08/29/2025
- Greg Harrison from Scotiabank set a target price of $57.0 on 08/06/2025
- Leland Gershell from Oppenheimer set a target price of $61.0 on 08/06/2025
- Josh Schimmer from Cantor Fitzgerald set a target price of $95.0 on 07/29/2025
- Danielle Brill from Truist Securities set a target price of $66.0 on 07/21/2025
- Biren Amin from Piper Sandler set a target price of $68.0 on 07/14/2025
- Andrew Tsai from Jefferies set a target price of $70.0 on 07/14/2025
Full Release
PALO ALTO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that an oral presentation of Phase 2 data in post-surgical hypoparathyroidism and two poster sessions on skeletal dysplasia data will be shared at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025, taking place in Seattle, WA from September 5 - 8, 2025.
Post-Surgical Hypoparathyroidism Oral Presentation:
The Oral Calcilytic Encaleret Reduced Urinary Calcium While Maintaining Blood Calcium in Individuals with Post-Surgical Hypoparathyroidism
Presenter:
Iris Hartley, M.D., National Institute of Dental and Craniofacial Research, National Institutes of Health
Date/time:
Saturday, September 6 at 11:30 am PT
Skeletal Dysplasia Poster Sessions:
Infigratinib Low Dose Therapy Is an Effective Strategy in Improving Bone Growth in a Hypochondroplasia Mouse Model
Presenter:
Bhavik Shah, Ph.D., Senior Vice President of Research, Genetic Medicine, Skeletal Dysplasia, BridgeBio
Date/time:
Friday, September 5 at 5:00 pm PT and Sunday, September 7 at 2:00 pm PT
Infigratinib Improves Skull Measures in a Mouse Model of Crouzon/Pfeiffer Syndromes
Presenter:
Bhavik Shah, Ph.D., Senior Vice President of Research, Genetic Medicine, Skeletal Dysplasia, BridgeBio
Date/time:
Saturday, September 6 at 2:00 pm PT
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit
bridgebio.com
and follow us on
LinkedIn
,
Twitter
,
Facebook
,
Instagram
,
and
YouTube
.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
[email protected]
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
[email protected]
